A Multi-Site Study to Evaluate the Safety and Effect of Study Drug on Participants With Rheumatoid Arthritis
Status:
Completed
Trial end date:
2007-10-18
Target enrollment:
Participant gender:
Summary
This study is a multicenter, double-blind, study to evaluate the safety and effectiveness of
treatment with LY2127399 (in addition to the standard of care treatment, methotrexate) for
participants with Rheumatoid Arthritis. Participants will receive three intravenous doses of
LY2127399 or placebo. Participants will participate in 10 or more visits to the study site,
over 6 months. Evaluation of safety and efficacy will be conducted throughout the study.